CN1546450A - Alkannin derivatives as immune inhibitors and metal complexes thereof - Google Patents
Alkannin derivatives as immune inhibitors and metal complexes thereof Download PDFInfo
- Publication number
- CN1546450A CN1546450A CNA2003101090577A CN200310109057A CN1546450A CN 1546450 A CN1546450 A CN 1546450A CN A2003101090577 A CNA2003101090577 A CN A2003101090577A CN 200310109057 A CN200310109057 A CN 200310109057A CN 1546450 A CN1546450 A CN 1546450A
- Authority
- CN
- China
- Prior art keywords
- acid
- shikonin
- formula
- iii
- unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An alkannin derivative as immuno-suppressive agent and its metallic complex compound with a chemical constitution formulas III and IV disclosed in the specification, wherein in formula III, R is C1-6 saturated, unsaturated and aromatic acyl, in formula IV, R is hydrogen, C1-6 saturated, unsaturated and aromatic acyl, M is metallic Cu, Ca, Zn. The present invention realizes immunological suppression effect, thus can be used for treating diseases relating to human body autoimmune including chronic infectious arthritis, scleredema, lupus erythematosus, HIV infection and malignant tumor.
Description
Technical field
The present invention relates to a kind of alkannin derivant and metal complex thereof, specifically is a kind of alkannin derivant and metal complex thereof as immunosuppressor.Belong to pharmaceutical field.
Background technology
Asian puccoon (Lishopermum eryhrorhizon) is a traditional Chinese medicine, medicinal its root.It is sweet, cold in nature to distinguish the flavor of, and returns Liver Channel, function cooling and activating blood, detoxifcation promoting eruption.Be applicable to that measles or febrile disease send out macula.Modern age, pharmaceutical research proof Asian puccoon had antibiotic, anti-inflammatory, effect such as antitumor.Its main component has Shikonin (shikoin I), acetylshikonin (Acetyl shikonin II) etc.
Find by literature search, the Shikonin that Xin Chen etc. delivers on " International Immunopharmacology " the 1st phase of calendar year 2001 P229-236, a component of antiinflammatoryChinese herbal medicine, selectively blocks chemokine binding to CC chemokinereceptor-1 (a kind of traditional Chinese medicine anti-inflammatory component Shikonin is impedance chemokine and CC-chemokine receptor-1 optionally) and the Shikonin that on " Antimicrobial Agents and Chemotherapy " 2003 the 47th volumes the 9th phase P2810-2816, delivers, a component of Chinese herbal medicine, inhibits chemokine receptot function and suppresses human immunodeficiencyvirus type-1 (a kind of traditional Chinese medicine composition Shikonin chemokine inhibiting function of receptors and suppress I type people self defective virus of exempting from service) has reported to have optionally by Shikonin chemokine (Chemokine) acceptor-I suppresses activity in the literary composition.May be used for the treatment of some the autoimmune inflammation disease and the defective virus of self exempting from service.Chemokine is the cytokine that a class has chemotaxis, and they can guide leucocyte migration, induce its activity, plays an important role in the human immunity reaction.The overexpression of chemokine or when being organized as the target of attack with normal health then causes some autoimmune disorder, as rheumatoid arthritis, multiple sclerosis, lupus erythematosus, organ transplant rejection etc.Chemokine also infects relevant with metastases and HIV.Therefore, CFI may be used for above-mentioned and the treatment autoimmunization diseases related.This article author has proposed Shikonin first to the restraining effect of Chemokine Receptors and predicted that Shikonin is used for the possibility of autoimmunization relative disease.But do not report the biological activity of alkannin derivant and complex compound thereof, do not report their restraining effect yet immunocyte.
Summary of the invention
The present invention is directed to the deficiency and the defective of existing invention, a kind of alkannin derivant and metal complex thereof as immunosuppressor is provided, make it solve the active stronger and lower immunosuppressor of toxicity, the derivative and the metal ion complex that have synthesized some Shikonins have been measured its restraining effect and cytotoxicity to immunocyte
The present invention implements by following technical solution, and the present invention is a raw material with Liaoning Asian puccoon, gets its root, passes through CO
2Critical extraction obtains total alkannin, then, and with CO
2Critical extract basic hydrolysis obtains Shikonin (I).
With Shikonin and various organic acid (as acetate, propionic acid, butyric acid, isopropylformic acid, α-Jia Jibingxisuan, Beta-methyl vinylformic acid, β, beta dimethylacrylic acid, phenylformic acid, p-nitrobenzoic acid) under DCC and DMAP catalysis, carry out condensation, obtaining with molecular formula (III) is the Shikonin ester derivative of representative.
With Shikonin and ester derivative thereof and metal ion (as Cu
++, Zn
++, Ca
++) complexing, obtaining with molecular formula (IV) is the complex compound of representative.
With immune cell proliferation method (H
3Method) and cell toxicant method (mtt assay) measuring the immunosuppressive action and the cytotoxicity of institute's synthetic compound, the results are shown in Table 1.
The result shows that the compound of the derivative general formula III representative of Asian puccoon has very strong immunosuppressive action when (0.1-100 μ g/ml) in the concentration range of experiment, but has cytotoxicity.The compound of general formula I V representative still keeps stronger immunosuppressive activity and does not have cytotoxicity when low concentration.Can be used for treatment with the autoimmunization diseases related.
Derivatives chemical structural formula (III) and the metal complex chemical structural formula (IV) thereof of the Asian puccoon that the present invention mentions are:
In the formula III; R represents saturated, the unsaturated and aromatic acyl group of 1-6 carbon atom; as R is ethanoyl (II), propionyl (III-1), butyryl radicals (III-2), isobutyryl (III-3), Alpha-Methyl acryl (III-4), Beta-methyl acryloyl (III-5), β, beta-dimethyl-acryl (III-6), benzoyl (III-7), p-nitrophenyl formyl radical (III-8).
Among the formula IV, R represents hydrogen, saturated, the unsaturated and aromatic acyl group of 1-6 carbon atom, and M represents metal Cu, Ca, Zn.As R=H, M=Cu (IV-1), R=H, M=Ca (IV-2), R=H, M=Zn (IV-3), R=Ac, M=Cu (IV-4), R=Ac, M=Ca (IV-5), R=Ac, M=Zn (IV-6).
The immunosuppression of table 1 part of compounds and cytotoxicity test result:
| Compound | Concentration (μ g/ml) | T cell inhibitory effect (%) | B cell proliferation suppresses (%) | Cytotoxicity (having/do not have) |
| ????I | ????100 ????10 ????1 | ????-100 ????-100 ????-99 | ????-100 ????-100 ????-51 | Have |
| ????II | ????100 ????10 ????1 | ????-100 ????-99 ????-17 | ????-100 ????-100 ????-15 | Have or not |
| ????III-1 | ????100 ????10 ????1 | ????-100 ????-99 ????-17 | ????-100 ????-98 ????-15 | Have or not |
| ????III-2 | ????100 ????10 ????1 | ????-100 ????-100 ????-22 | ????-100 ????-100 ????-7 | Have or not |
| ????III-3 | ????100 ????10 ????1 | ????-100 ????-100 ????-11 | ????-100 ????-100 ????-7 | Have or not |
| ????III-4 | ????100 ????10 ????1 | ????-100 ????-100 ????-4 | ????-100 ????-98 ????-5 | Have or not |
| ????III-5 | ????100 ????10 | ????-84 ????-11 | ????-27 ????-5 | Have or not |
| ????1 | ????-4 | ????-5 | Do not have | |
| ????III-6 | ????100 ????10 ????1 | ????-100 ????-56 ????-2 | ????-100 ????-10 ????-2 | Have or not nothing |
| ????III-7 | ????100 ????10 ????1 | ????-100 ????-67 ????1 | ????-100 ????-8 ????-17 | Have or not |
| ????III-8 | ????100 ????10 ????1 | ????-17 ????5 ????1 | ????-25 ????-9 ????-15 | Have or not nothing |
| ????IV-1 | ????100 ????10 ????1 | ????-100 ????-23 ????-14 | ????-100 ????-62 ????-4 | Have or not nothing |
| ????IV-2 | ????100 ????10 ????1 | ????-100 ????-100 ????-31 | ????-100 ????-100 ????-4 | Have or not nothing |
| ????IV-3 | ????100 ????10 ????1 | ????-100 ????-100 ????-31 | ????-100 ????-100 ????-26 | Have or not nothing |
| ????IV-4 | ????100 ????10 ????1 ????0.1 | ????-100 ????-99 ????-100 ????-67 | ????-100 ????-98 ????-100 ????-87 | Have or not nothing |
| ????IV-5 | ????100 ????10 ????1 ????0.1 | ????-100 ????-100 ????-100 ????-95 | ????-100 ????-100 ????-97 ????-78 | Have or not nothing |
| ????IV-6 | ????100 ????10 | ????-100 ????-99 | ????-100 ????-100 | Have |
| ????1 ????0.1 | ????-99 ????-26 | ????-96 ????-55 | Do not have |
The present invention has substantive distinguishing features and marked improvement, and these compounds have immunosuppressive action, can be used for and human body self immunity diseases associated, and comprising: rheumatoid arthritis, multiple sclerosis disease, lupus erythematosus, HIV infect, malignant tumour.
Embodiment
Experimental section
1, the preparation of Shikonin
Get the CO of Liaoning gromwell root crude drug
2Supercritical extract 10 gram is dissolved in the NaOH solution of 0.2mol/l of 500ml, stirring at room 24 hours, and the centrifugal insolubles of removing merges supernatant liquor, adds the H of 0.5mol/l
2SO
4Solution becomes redness until solution, places 2 hours, and is centrifugal, gets red precipitate, washing, and drying gets Shikonin crude product 5g, and the sherwood oil recrystallization gets the crystal 2 .5g that sorrel has metalluster, yield 25%.Fusing point 148-149 ℃, H-NMR (CDCl
3) δ: 1.651,1.755 (s, each 3H, 2CH
3), 2.311-2.387 (1H, m ,-CHa), 2.623-2.660 (1H, m ,-CHb), 4.911 (1H, d, J=7.2,4.0 ,-OCH-), 5.202 (1H, dd, J=8.0,6.8 ,=CH-), 7.165 (s, 1H, Quin-H), 7.192 (2H, 2Ar-H), 12.494,12.598 (each 1H, s, 2Ar-OH), consistent with bibliographical information (Botany Gazette, 1989,31 (7), 549-553).
2, the preparation of Shikonin ester derivative
Logical method: get the some grams of Shikonin crude product, be dissolved in exsiccant CH
2Cl
2In, after treating all to dissolve, add the organic acid (lipid acid, unsaturated acid, aromatic acid) of 1-2 times of molar weight, and the DCC of 2-3 times of molar weight and DMAP, room temperature-30 ℃ stirring 1-12 hour, stopped reaction.The filtering insolubles, filtrate washing 3 times adds anhydrous Na
2SO
4Drying, decompression steams solvent, and crude product is used the appropriate solvent recrystallization through chromatographic separation, can get the ester derivative of Shikonin.
(1) acetylshikonin: get Shikonin 1.44g, be dissolved in exsiccant CH
2Cl
2In, after treating all to dissolve, add the 1g Glacial acetic acid, and 2g DCC and 0.3g DMAP, stirring at room 1 hour, stopped reaction.The filtering insolubles, filtrate washing 3 times adds anhydrous Na
2SO
4Drying removes solvent under reduced pressure, gets crude product, uses the sherwood oil recrystallization, obtains the crystal 1.15g that dark red has metalluster, yield 70%.Fusing point: 106-107 ℃.
1H-NMR (CDCl
3) δ: 1.579,1.694 (each 3H, S, 2CH
3), 2.142 (3H, S, CH
3C=O), 2.444-2.518 (m, 1H ,-CHa), 2.580-2.650 (1H, m ,-CHb), 5.122 (1H, t, J=9.6,-CH=), 6.021 (1H, dd, J=9.2,6.2,-OCH-), 6.991 (1H, s, Quin-H), 7.186 (2H, s, 2Ar-H), 12.433,12.589 (each 1H, s, 2Ar-OH), consistent with bibliographical information (Botany Gazette, 1989,31 (7), 549-553).
(2) Alpha-Methyl acryloyl Shikonin: get Shikonin 2.88g, be dissolved in exsiccant CH
2Cl
2In, after treating all to dissolve, add the 2g α-Jia Jibingxisuan, and 4g DCC and 0.6g DMAP, 30 ℃ were stirred stopped reaction 5 hours.The filtering insolubles, filtrate washing 3 times adds anhydrous Na
2SO
4Drying below 50 ℃, removes solvent under reduced pressure, and silica gel column chromatography separates, and use sherwood oil: the moving phase wash-out of ethyl acetate=20: 1, must product 1.76g, and yield 49.4%.Use recrystallizing methanol, obtain the crystal that redness has metalluster, fusing point: 83-84 ℃.
1H-NMR (CDCl
3) δ: 1.563, each 3H of 1.580[, s ,=C (CH
3)
2], 1.976 (3H, s ,=C-CH
3), 2.505-2.541 (1H, m ,-CHa), 2.646 (1H, m ,-CHb), 5.118 (1H, t, J=7.2 ,-CH=), 5.659,6.208 (each 1H, s ,=CH
2), 6.062 (1H, dd.J=7.2,4.8 ,-OCH-), 6.967 (1H, s, Quin-H), 7.187 (2H, s, 2Ar-H), 12.431,12.601 (each 1H, s, 2Ar-OH).
(3) p-nitrophenyl formyl Shikonin: get Shikonin 1g, be dissolved in exsiccant CH
2Cl
2In, after treating all to dissolve, add the 0.5g p-nitrobenzoic acid, and 2g DCC and 0.3g DMAP, 30 ℃ were stirred stopped reaction 12 hours.The filtering insolubles, filtrate washing 3 times adds anhydrous Na
2SO
4Drying removes solvent under reduced pressure below 50 ℃, and silica gel column chromatography separates, and uses sherwood oil: the moving phase wash-out of ethyl acetate=20: 1, get product 0.83g, yield 58.5% is used the sherwood oil recrystallization, obtaining dark red has the crystal of metalluster, fusing point: 143-144 ℃
1H-NMR (CDCl
3) δ: 1.611,1.689 (each 3H, s, 2CH
3), 2.644-2.699 (1H, m ,-CHa), 2.751-2.780 (1H, m,-CHb), 5.191 (1H, t, J=7.2 ,-CH=), 6.294 (1H, dd, J=6.8,5.2 ,-OCH-), 7.06 (1H, s, Quin-H), 7.187 (2H, s, 2Ar-H), 8.247 (2H, d, J=9.2,2 ' 6 '-Ar-H), 8.339 (2H, d, J=9.2,3 ' 5 '-Ar-H), 12.386,12.629 (each 1H, s, 2Ar-OH).
3, the metal network of Shikonin and ester thereof and the preparation of thing
Logical method: with some gram Shikonins of minimum acetone solution or Shikonin ester; In addition with the Cu (Ac) of 2 times of molar weights of minimum water dissolution
2, Zn (Ac)
2, Ca (Ac)
2Both are mixed, produce precipitation, filter, be drying to obtain metal complex.
Example:
(1) acetylshikonin copper complex: get acetylshikonin 176mg, be dissolved in the 3ml acetone, other gets neutralized verdigris 194mg and is dissolved in the 5ml water, with the two mixing, places, and separates out precipitation, filter, and a small amount of washing, drying gets complex compound 229mg, yield 94.2%.
(2) acetylshikonin zinc complex: get acetylshikonin 236mg, be dissolved in the 5ml acetone, other gets zinc acetate 263mg and is dissolved in the 5ml water, with the two mixing, places, and separates out precipitation, filter, and a small amount of washing, drying gets complex compound 309mg, yield 93.8%.
(3) acetylshikonin calcium complex: get acetylshikonin 250mg, be dissolved in the 5ml acetone, other gets calcium acetate 240mg and is dissolved in the 8ml water, with the two mixing, places, and separates out precipitation, filter, and a small amount of washing, drying gets complex compound 298mg, yield 96.4%.
4, cell inhibitory effect experiment
1), cell proliferation method (H
3Method)
(1) takes off vertebra and put to death mouse, aseptic its spleen of getting.Spleen is ground with sheet glass, cross film, centrifugal 5 minutes in 1200rpm.Supernatant discarded.Precipitation adds the about 1ml of each spleen of erythrocyte cracked liquid, and mixing left standstill 1 minute, adds PBS, and is centrifugal.Add PBS again, cross film, centrifugal.Behind last cell washing 1-2 time, with containing the RPMI-1640 nutrient solution of 10% calf serum with cell concn furnishing 4 * 10
6/ ml.
(2) every hole adds the cell suspension of 100 μ l, the sample of 50 μ l, ConA or the LPS of (contrast adds the nutrient solution of 50 μ l) and 50 μ l, cumulative volume 200 μ l in 96 orifice plates.Every experimental group is established 3 multiple holes, and other establishes 3 holes and is not added with the background contrast of a mitogen as cell proliferation.
(3) cell is in containing 5%CO
237 ℃ of incubators in cultivate, cultivate to finish preceding 12 hours every holes and add 25 μ l
3The H-thymidylic acid.
(4) continue to be cultured to experiment and finish, then that culture plate is frozen in-20 ℃ of refrigerators; Cell with freeze thawing during mensuration is collected on the glass fibre membrane with the cell harvesting instrument, adds to read on the Beta calculating instrument behind the scintillation solution to mix cell DNA
3H-thymidylic acid amount is represented the situation of cell proliferation with the cpm value.
2), cell toxicant method (mtt assay)
(1) gets the ICR mouse and take off vertebra execution, get spleen after the sterilization.Spleen is ground with sheet glass, cross film, centrifugal 5 minutes in 1200rpm.Supernatant discarded.Precipitation adds erythrocyte cracked liquid 2-4ml, and mixing left standstill 1 fen, adds PBS, and is centrifugal.Add PBS again, cross film.Behind last cell washing 1-2 time, cell concn is transferred to 5 * 10
6Individual/ml.(5 * 10
5Individual/well)
(2) every hole adds the cell suspension of 90 μ l, ConA or the LPS of the sample of 45 μ l (contrast adds the nutrient solution of 45 μ l) and 45 μ l, cumulative volume 180 μ in 96 orifice plates.Every experimental group is established 3 multiple holes, and other establishes 3 holes and is not added with the background contrast of a mitogen as cell proliferation.
(3) 37 ℃, 5%CO
2Cultivated 48 hours in the incubator, 4-5 hour every hole adds MTT 18 μ l before finishing to cultivate.
(4) cultivate when finishing, add lysate 90 μ l, placed about 6-7 hour, (Bio-Rad Model550 Japan) surveys the OD value in the 570nm place with microplate reader.
Claims (2)
1, a kind of alkannin derivant and metal complex thereof as immunosuppressor is characterized in that, derivatives chemical structural formula II I of Asian puccoon and metal complex chemical structural formula IV thereof are:
In the formula III: R represents saturated, the unsaturated and aromatic acyl group of 1-6 carbon atom; Among the formula IV: R represents hydrogen, saturated, the unsaturated and aromatic acyl group of 1-6 carbon atom, and M represents metal Cu, Ca, Zn.
2, alkannin derivant and metal complex thereof as immunosuppressor according to claim 1, it is characterized in that, with Shikonin and acetate, propionic acid, butyric acid, isopropylformic acid, α-Jia Jibingxisuan, Beta-methyl vinylformic acid, β, beta dimethylacrylic acid, phenylformic acid, the various organic acids of p-nitrobenzoic acid carry out condensation under DCC and DMAP catalysis, obtaining with the molecule formula III is the Shikonin ester derivative of representative; With Shikonin and ester derivative and Cu
++, Zn
++, Ca
++Complexing of metal ion, obtaining with molecular formula IV is the complex compound of representative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310109057 CN1271032C (en) | 2003-12-04 | 2003-12-04 | Alkannin derivatives as immune inhibitors and metal complexes thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310109057 CN1271032C (en) | 2003-12-04 | 2003-12-04 | Alkannin derivatives as immune inhibitors and metal complexes thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1546450A true CN1546450A (en) | 2004-11-17 |
| CN1271032C CN1271032C (en) | 2006-08-23 |
Family
ID=34335001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310109057 Expired - Fee Related CN1271032C (en) | 2003-12-04 | 2003-12-04 | Alkannin derivatives as immune inhibitors and metal complexes thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1271032C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622506B2 (en) | 2006-04-07 | 2009-11-24 | Sunten Phytotech Co., Ltd. | Naphthalenedione compounds for treating inflammation related disorders and microbial infection |
| CN101182290B (en) * | 2007-12-13 | 2010-08-11 | 上海交通大学 | Shikonin dimethyl ether 6-site side chain isomer as well as derivatives and synthesis method thereof |
| CN102198120A (en) * | 2010-03-26 | 2011-09-28 | 山东靶点药物研究有限公司 | Medicinal use of lithospermi naphthoquinone compounds |
| CN102198124A (en) * | 2010-03-26 | 2011-09-28 | 山东靶点药物研究有限公司 | Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof |
| CN102211997A (en) * | 2011-03-28 | 2011-10-12 | 上海交通大学 | Alkannin naphthazarine mother nucleus acetoxylation derivative as well as preparation method and application thereof |
| CN102552227A (en) * | 2010-12-30 | 2012-07-11 | 浙江大学 | Application of shikonin derivatives to preparation of pyruvate kinase inhibitors |
| CN105530813A (en) * | 2013-07-19 | 2016-04-27 | 里奇·麦卡洛 | Immuno-modulators for treating functional epithelial syndromes |
| CN107383074A (en) * | 2017-06-05 | 2017-11-24 | 李丹 | The preparation method of benzoxazine with platelet aggregation inhibitory activity and pyrazoles calcium composition |
| CN108939054A (en) * | 2018-08-03 | 2018-12-07 | 广州加原医药科技有限公司 | A kind of Chinese medicine composition nanometer formulation |
| CN116172992A (en) * | 2022-12-12 | 2023-05-30 | 吉林大学 | Water-phase dispersed transition metal ion/shikonin composite nano particle and two-phase preparation method thereof |
-
2003
- 2003-12-04 CN CN 200310109057 patent/CN1271032C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622506B2 (en) | 2006-04-07 | 2009-11-24 | Sunten Phytotech Co., Ltd. | Naphthalenedione compounds for treating inflammation related disorders and microbial infection |
| CN101182290B (en) * | 2007-12-13 | 2010-08-11 | 上海交通大学 | Shikonin dimethyl ether 6-site side chain isomer as well as derivatives and synthesis method thereof |
| CN102198120A (en) * | 2010-03-26 | 2011-09-28 | 山东靶点药物研究有限公司 | Medicinal use of lithospermi naphthoquinone compounds |
| CN102198124A (en) * | 2010-03-26 | 2011-09-28 | 山东靶点药物研究有限公司 | Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof |
| CN102198120B (en) * | 2010-03-26 | 2014-06-18 | 苏州雷纳药物研发有限公司 | Medicinal use of lithospermi naphthoquinone compounds |
| CN102198124B (en) * | 2010-03-26 | 2014-10-29 | 山东靶点药物研究有限公司 | Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof |
| CN102552227A (en) * | 2010-12-30 | 2012-07-11 | 浙江大学 | Application of shikonin derivatives to preparation of pyruvate kinase inhibitors |
| CN102211997A (en) * | 2011-03-28 | 2011-10-12 | 上海交通大学 | Alkannin naphthazarine mother nucleus acetoxylation derivative as well as preparation method and application thereof |
| CN105530813A (en) * | 2013-07-19 | 2016-04-27 | 里奇·麦卡洛 | Immuno-modulators for treating functional epithelial syndromes |
| CN107383074A (en) * | 2017-06-05 | 2017-11-24 | 李丹 | The preparation method of benzoxazine with platelet aggregation inhibitory activity and pyrazoles calcium composition |
| CN108939054A (en) * | 2018-08-03 | 2018-12-07 | 广州加原医药科技有限公司 | A kind of Chinese medicine composition nanometer formulation |
| CN116172992A (en) * | 2022-12-12 | 2023-05-30 | 吉林大学 | Water-phase dispersed transition metal ion/shikonin composite nano particle and two-phase preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1271032C (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4397688B2 (en) | Use of stilbene compounds in the manufacture of a medicament for the prevention and treatment of diabetes or retrovirus-related diseases | |
| CN1271032C (en) | Alkannin derivatives as immune inhibitors and metal complexes thereof | |
| US8105636B2 (en) | Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus amboinicus extracts | |
| CN102432620A (en) | Resveratrol tetramer compound, its preparation method and application | |
| KR101103426B1 (en) | Pharmaceutical composition for treating inflammatory bowel disease comprising mollugin or its analogues | |
| KR100306430B1 (en) | Colchicine skeletal compounds and their use as pharmaceuticals and compositions containing them | |
| CN102532345A (en) | O-unsaturated fatty acid acylated chitosan oligosaccharides as well as preparation and application thereof | |
| US8580847B2 (en) | Antrocin containing pharmaceutical compositions for inhibiting cancer cells | |
| CN100434419C (en) | Compound of monocyclic polysubstitution saturated cyclohexanones, prepartion method and usage | |
| KR100202320B1 (en) | Pharmaceutically applicable anthracene compounds | |
| KR20210094997A (en) | Pharmaceuticals or health functional foods for treating or preventing non-alcoholic fatty acid liver disease comprising novel compounds isolated from Cervus nippon | |
| JP3740284B2 (en) | Novel compound having antimalarial activity or salt thereof | |
| TW201023862A (en) | Pharmaceutical compositions and extracts containing kinsenoside for inhibiting activation of macrophage, inhibiting formation of osteoclasts, inhibiting function of osteoclasts, and/or activating osteoblasts and uses of the same | |
| CZ312592A3 (en) | Bis(phenyl)ethane derivatives, process of their preparation and pharmaceutical composition in which said derivatives are comprised | |
| JP2001328937A (en) | Multiple drug resistant tumor-conquering agent and method of production for the same | |
| JPH06247851A (en) | Carcinogenesis promotion suppressor | |
| KR100979921B1 (en) | Stereum ostrea extracts, lactone compounds isolated therefrom and antiobesity composition comprising the same | |
| KR20010015872A (en) | Apoptosis inducer | |
| JP5995235B2 (en) | Use of rosmarinic acid and its derivatives to treat ciguatera | |
| CN113384562B (en) | Application of diterpenoid compound in preparation of beta-glucuronidase activity inhibitor | |
| CN1104437C (en) | Compound extracted from heroubill herb and its medicinal preparation | |
| CN100582110C (en) | Cyclohexanone analog saturated triring(bridge)compound and its preparation method and uses | |
| CN110563688B (en) | Benzopyran compounds with anti-complement activity and application thereof | |
| CN1872828B (en) | Monocyclic polysubstitution cyclohexenol, and compound of ketones, and preparation method, and usage | |
| JP6329156B2 (en) | Compound, pharmaceutical, anti-inflammatory agent and method for producing compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |